2020-2027 Analysis and Review Dosulepin Market

Dosulepin Market

Dosulepin Market By Treatment (Major Depressive Disorders and Psychogenic Facial Pain), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

14-04-2020 REP-HC-5065 40 Tables 108 pages Format

The dosulepin market was valued at USD160.6Mn by 2019. Rising prevalence of anxiety and mood disorders throughout the glob associated with increasing stress, unhealthy lifestyle, alcohol consumption, etc. primarily drive the dosulepin market growth. The effective implementation of guidelines pertaining to mental health worldwide will further accentuate the dosulepin market growth.

 Dosulepin Market

Dosulepinis a tricyclic antidepressant is popularly known as Dothep, Prothiaden, Thaden, etc, it exerts its antidepressant activity by inhibiting the reuptake of serotonin and noradrenaline in the central nervous system. It has a high toxicity profile and needs to be taken under medical supervision. The drug posology is oral administration of drug initially 25mg tid with gradual increase to 50 mg tid, if need be the dose might be adjusted as a single dose of 225mg/day at night in cases of severe depression.

The major segments related to the dosulepin market are:

By Treatment (2017–2027; US$ Mn)

Major Depressive Disorder

Psychogenic Facial Pain

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment(2017–2027; US$ Mn)

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global dosulepin market
  • The overall segmentation of the dosulepin market, by treatment, distribution channel, and geography is minutely studied. Major depressive disorder and hospital pharmacy are dominating the treatment and distribution channel segments respectively
  • Rising prevalence of major depressive disorder throughout the globe
  • Diligent research activities conducted to understand the clinical application of dosulepin in the treatment of psychogenic facial pain

Report gist?

  • The study of the global dosulepin market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers qualitative and quantitative analysis of the overall market segmented on the basis of treatment and distribution channel and categorization of the same at the geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. Compounded annual growth rate is calculated for the respective segments from 2020 to 2027
  • The study includes the profiles of major market players with a significant global and regional presence along with top company positioning

Significant customers?

  • This study is suitable for industry participants and stakeholders in the biopharmaceutical companies engaged in manufacturing and marketing of dosulepin for the treatment of major depressive disorder worldwide
  • The report will benefit researchers engaged in understanding the pathophysiology of psychogenic facial pain and its treatment by prescribing dosulepin
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to dosulepin market
  • Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies

Segment Analysis

Major depressive disorders are presently representing the largest market share in the dosulepin market. It is characterized by low mood for at least 2 weeks which is usually accompanies by low self-esteem, lethargy, neuropsychic pain, hallucinations, etc. It is responsible for the death of about 2-8% of the adult population by committing suicide. As per the research citings brought forward by the National Institute of Health (NIH), approximately 216 million people worldwide are suffering from a major depressive disorder. Psychogenic facial pain is going to register rampant market growth in the near future on account of the rising prevalence of this somatoform disorder associated with facial neuropathy in the elderly population throughout the globe. The clinical manifestations associated with psychogenic facial pain are paresthesia, throbbing pain, allodynia, etc.

Hospital pharmacy is dominating the distribution channel segment for the dosulepin market. The drug is associated with high toxicity profile and contraindications and hence hospital pharmacists are crucial in the compounding precise drug posology to negate the occurrence of any drug-related adverse events. Retail pharmacy is gaining strong grounds in the developing regions on account of the prospering generic drugs market and government intervention in providing essential medicines to its citizens at subsidized rates at generic retail pharmacies.

Europe is the clear leader in the regional segment for the dosulepin market. The key factor responsible for its market dominance is the rising prevalence of major depressive disorder in the region. According to the latest research citings provided by the World Health Organization (WHO), annually 25% of the population is suffering from depression or anxiety in the European region. Furthermore the healthcare burden associated with the treatment of anxiety and mood disorders in the European Union region is approximately €170 billion per year. The presence of major players in the region such as Teva Pharmaceuticals Industries Ltd., Teofarma S.R.L., Mawdsley-Brooks & Company Ltd, etc. further accentuate the market growth in the region. Dosulepin is not approved by the USFDA and hence it is not prescribed as an antidepressant medication in the United States and Canada. Asia Pacific is anticipated to be the fastest-growing regional market during the forecast period. Rising prevalence of mood disorders, anxiety, psychogenic facial pain etc., primarily drive the market growth in the region. Additionally, developing healthcare infrastructure and flourishing generic drugs market will further propel the market growth in the region.

Select License Type

$4,600
$6,600
$9,500

Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.